Locally Advanced Rectal Cancer
Conditions
Keywords
Locally Advanced Rectal Cancer, PD-1 inhibition, neoadjuvant therapy
Brief summary
The purpose of this study was to evaluate the effect of capecitabine-based long-term radiotherapy followed by 3 cycles Sintilimab (PD-1 inhibitor) in patients with locally advanced rectal cancer.
Detailed description
Investigator designed a single-arm, open-label, phase II trial and the purpose of this study is to observe and evaluate the efficacy and safety of capecitabine-based long-term radiotherapy followed by 3 cycles Sintilimab (PD-1 inhibitor) for locally advanced rectal cancer.Participants will accept capecitabine-based long-term radiotherapy(50.4Gy radiation) followed by 200mg Sintilimab each time for 3 times, with 2-week intervals. The primary endpoint is pCR rate, and secondary endpoints include sphincter-preserving rate, adverse event rates.
Interventions
RADIATIONradiation
45 Gy radiation dose in 25 fractions to the pelvis
200mg Sintilimab after radiation (3 times, 2-week interval)
PROCEDURETME surgery
TME surgery for 6\ 8 weeks after radiation
Sponsors
Peking University People's Hospital
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Masking description
Masking is not practically possible
Eligibility
Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
* aged 18\ 75 * ECOG score 0\ 2 * biopsy diagnosed rectal adenocarcinoma, distal margin within 10cm to anal verge * no distant metastasis, staged II/III (T4b excluded) by MRI * maximum diameter of rectal cancer lesion≥10mm according to baseline CT or MR * willing and able to comply with study protocol * consent to the use of blood and tissue specimens for study * no history of previous anti-tumor treatment (e.g. radiation, chemo, immuno, bio, herbal, etc.) * no disorders/diseases of immune system (e.g. systemic lupus erythematosus, rheumatoid arthritis, systemic vasculitis, scleroderma, pemphigus, dermatomyositis, mixed connective tissue disease, autoimmune hemolytic anemia, hyperthyroidism/hypothyroidism, ulcerative colitis, autoimmune hemolytic anemia, HIV infection, etc.) * no significant dysfunction of major viscera (e.g. heart, lung, liver, kidney, etc.) * no jaundice or gastrointestinal obstruction * no acute/ongoing infection * no significant irregularities in blood routine test and biochemical test results, particular requirements include: neutrophils≥1.5×109/L, HGB≥80g/L, platelet≥100×109/L, serum creatinine≤1.5×ULN, total bilirubin≤1.5×ULN, ALT、AST≤2.5×ULN * no social or mental disorder * for women of child-bearing age, a negative result of serological pregnancy test is required, and effective contraception measures from inclusion till 60 days after the last dose of study drug is required
Exclusion criteria
* multiple cancers, or with concomitant malignant tumors besides rectal cancer * having received any anti-cancer treatment (surgery, drugs, etc.) in the past 5 years * history of recent major surgery * with condition that affects the absorption of capecitabine via gastrointestinal tract (e.g. inability to swallow, nausea, vomiting, chronic diarrhea, etc.) * with uncontrolled, severe, concomitant diseases of any sort * allergic to any of the ingredients under study * estimated survival ≤ 5 years due to any reason * preparing for or having previously received organ or bone marrow transplant * having received immunosuppressive or systemic hormone therapy for immunosuppressive purposes within 1 month prior to inclusion * for patients with history of disorder of central nervous system, investigator discretion is required as to whether the clinical severity prevents the signing of informed consent or affects the patient or oral medication compliance * with other conditions/issues that may affect the study results or cause the study treatment to be terminated halfway (e.g. alcoholism, drug abuse, etc.) * pregnant or lactating women, or women intending on conception during treatment period
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| pCR rate | within 1 week after surgery | pathological complete response rate |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| sphincter preserving rate | instantly after surgery | proportion of patients with preserved anal sphincter |
| immune-related adverse event rate | from commencing of PD-1 inhibition to the 30th day after surgery | adverse event rate that is deemed to be associated with PD-1 inhibition |
| treatment-related adverse event rate | from commencing of treatment to the 30th day after surgery | adverse event rate that is deemed to be associated with all treatments |
| incidence rate of surgical complications | within 30 days after surgery | incidence rate of surgical complications within 30 days after surgery |
Countries
China
Outcome results
None listed